{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:47:56Z","timestamp":1774018076506,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>There is a paucity of data evaluating early initiation of sodium\u2010glucose cotransporter\u20102 inhibitors (SGLT2i) in patients with diabetes following acute coronary syndrome (ACS) and coronary artery bypass graft surgery (CABG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe the efficacy and safety of SGLT2i initiated early after CABG in patients with type 2 diabetes who experienced ACS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective cohort study of patients with type 2 diabetes (T2DM) who experienced ACS and subsequent CABG\u00a0with follow up at 3 and 12\u2009months. Patients who filled a SGLT2i prescription within 14\u2009days of discharge were allocated to the SGLT2i group and those who did not were included in the no SGLT2i group. The primary efficacy end point was first occurrence of a 4\u2010point Major Adverse Cardiovascular Event (MACE), and the primary safety end point was a composite of hypoglycemia, hypotension, diabetic ketoacidosis, acute kidney injury, and urinary tract infection. Secondary end points included a comparative analysis of the primary outcome, 30\u2010day readmission rates, and subgroup analyses of key populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1629 patients were included: 226 received a SGLT2i within 14\u2009days of discharge and 1403 did not. At 12\u2009months, 8.9% and 15.3% of patients experienced MACE in the SGLT2i and no SGLT2i groups, respectively (adjusted Hazard Ratio [aHR] 0.65, 95% confidence interval [CI] 0.41\u20131.04). The primary safety outcome occurred in 12.0% of the SGLT2i group and 19.1% of the no SGLT2i group at 12\u2009months (aHR 0.68, 95% CI 0.45\u20131.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Early initiation of SGLT2i use was not associated with a reduction in MACE in patients with T2DM who experienced ACS and underwent subsequent CABG surgery. However, no apparent safety concerns were identified. Adequately powered trials are required to confirm this finding.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.4620","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T02:30:35Z","timestamp":1729909835000},"page":"841-850","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["<scp>ECLIPSES<\/scp>: Early initiation of sodium glucose <scp>cotransporter<\/scp>\u20102 inhibitors for <scp>cardiovascular<\/scp> protection in patients with type 2 diabetes following acute coronary syndrome and <scp>subsequent<\/scp> coronary artery bypass graft surgery"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6143-8884","authenticated-orcid":false,"given":"Lena","family":"Makortoff","sequence":"first","affiliation":[{"name":"Pharmacy Services, Alberta Health Services  Calgary Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-3987","authenticated-orcid":false,"given":"Karen L.","family":"Then","sequence":"additional","affiliation":[{"name":"Faculty of Nursing University of Calgary  Calgary Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9770-9844","authenticated-orcid":false,"given":"Melissa","family":"Dutchak","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Alberta Health Services  Calgary Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4541-2920","authenticated-orcid":false,"given":"Meng","family":"Lin","sequence":"additional","affiliation":[{"name":"Alberta SPOR SUPPORT Unit Data and Research Services University of Alberta  Edmonton Alberta Canada"},{"name":"Alberta Health Services Provincial Research Data Services  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-4469","authenticated-orcid":false,"given":"Erik","family":"Youngson","sequence":"additional","affiliation":[{"name":"Alberta SPOR SUPPORT Unit Data and Research Services University of Alberta  Edmonton Alberta Canada"},{"name":"Alberta Health Services Provincial Research Data Services  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6012-2882","authenticated-orcid":false,"given":"Cheryl","family":"Harten","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Alberta Health Services  Calgary Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000141"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.17-191"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2017.10.029"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezt017"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211585"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300286"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314051"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4644-9"},{"issue":"10","key":"e_1_2_9_13_1","first-page":"1225","article-title":"Overview of the Alberta provincial project for outcome assessment in coronary heart disease. On behalf of the APPROACH investigators","volume":"16","author":"Ghali W","year":"2000","journal-title":"Can J Cardiol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab392"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-6-48"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000174293.17959.a1"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092286"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14261"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.122.009078"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","unstructured":"ColacciM FralickJ OdutayoA FralickM.SGLT2 inhibitors and the risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta\u2010analysis.medRxiv.2021:2021.03.17.21253796.","DOI":"10.1101\/2021.03.17.21253796"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9090536"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01455-2"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_566_18"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.031"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.08.064"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","unstructured":"DixitNM Shah S Ziaeian B Fonarow GC Hsu JJ.Optimizing guideline\u2010directed medical therapies for heart failure with reduced ejection fraction during hospitalization;2021[Accessed 16 May 2023]. \u00a0https:\/\/www.uscjournal.com\/articles\/optimizing\u2010guideline\u2010directed\u2010medical\u2010therapies\u2010heart\u2010failure\u2010reduced\u2010ejection\u2010fraction","DOI":"10.15420\/usc.2020.29"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2020.12.015"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-022-01822-1"},{"key":"e_1_2_9_31_1","volume-title":"Product Monograph \u2013 Jardiance (Emplagliflozin)","author":"Boehringer Ingelheim Ltd","year":"2016"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac494"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.777083"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2021.108057"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.10.064"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-1201"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01440-5"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001821"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.4620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:46:25Z","timestamp":1761043585000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.4620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/phar.4620"],"URL":"https:\/\/doi.org\/10.1002\/phar.4620","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"2024-06-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}